Details of Drug-Drug Interaction
| Drug General Information (ID: DDIF9V18TH) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Penicillamine | Drug Info | Aurothioglucose | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antidotes | Antirheumatics | |||||||
| Structure | |||||||||
| Mechanism of Penicillamine-Aurothioglucose Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Additive immunosuppressive effects Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Penicillamine | Aurothioglucose | |||||||
| Mechanism 1 | Myelosuppressive effects | Myelosuppressive effects | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Immunosuppressive effects | ||||||||
| Factor Description | Immunosuppression is when your immune system is not functioning as it should. The immune system is made up of cells, tissues and organs that help the body fight off infections. If the immune system is suppressed, an infection that your body was able to control may become serious or even fatal. | ||||||||
| Mechanism Description |
|
||||||||
| Increased risk of nephrotoxicity Click to Show/Hide Mechanism Graph | |||||||||
 |
|||||||||
| Drug Name | Penicillamine | Aurothioglucose | |||||||
| Mechanism 2 | Nephrotoxicity | Nephrotoxicity | |||||||
| Key Mechanism Factor 2 | |||||||||
| Factor Name | Nephrotoxicity | ||||||||
| Factor Description | The combination of drugs that can induce nephrotoxicity may increase the risk of kidney injury. When kidney injury occurs, the inability to remove excess urine and waste from the body can lead to high levels of urea nitrogen, creatinine, and electrolytes (such as potassium and magnesium) in the blood. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Penicillamine and gold therapy should not be administered concurrently. Penicillamine may be prescribed following discontinuation of gold therapy, although some have suggested waiting a period of at least six months between treatments. Patients should be monitored closely and advised to notify their physician if they experience signs and symptoms of penicillamine toxicity such as fever, chills, sore throat, unusual bruising or bleeding, hematuria, coughing, wheezing, unexplained shortness of breath, muscle weakness, or double vision. | ||||||||